Search results
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in...
WTNH-TV New Haven· 4 days agoUpon the execution of the agreement, Hanmi Pharmaceutical will conduct a phase 1 clinical trial to...
ESMO Recap: Adjuvant Vs. Neoadjuvant Therapy in Melanoma
Medscape· 3 days agoSapna Patel presented the first abstract, and it was a follow-up on some very nice work from the...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days agoPhase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC ...
NHS trials first personal skin cancer jab that can halve risk of death
The Telegraph via Yahoo News· 2 days agoIt is also undergoing early testing on other cancers. Around 70 Britons are set to take part in a...
HOOKIPA advances HPV cancer trial with FDA nod By Investing.com
Investing.com· 3 days agoHOOKIPA Pharma Inc. (NASDAQ: HOOK), a clinical-stage biopharmaceutical company, has announced the...
Man receives world’s first melanoma vaccine — trial underway
New York Post· 2 days agoSome of the participants will get a placebo shot though none will know what they are receiving....
H.C. Wainwright Cuts HOOKIPA Pharma Shares target on Narrower HB-200 Target Population By...
Investing.com· 2 days agoThe adjustment followed HOOKIPA Pharma's announcement regarding the trial design of a Phase 2/3...
British man tests first personalised melanoma vaccine
BBC via Yahoo News· 2 days agoUniversity College London Hospitals (UCLH) doctors are giving it alongside another drug, ...
U.K. Tests World-First Personalized Skin Cancer Vaccine
Forbes· 2 days agoBritish patients are trying a first-of-its-kind customized vaccine for skin cancer as part of a...
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Morningstar· 4 days agoMedia Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9% response rate, the primary endpoint of the studyData